Worldwide Clinical Trials (Worldwide), a global full-service contract research organisation, has appointed Alessandra Vignola as president of the cardiovascular and metabolic business unit. Vignola brings more than 30 years of experience in the pharmaceutical and clinical research industry, enhancing the company’s leadership in these therapeutic areas.
Vignola’s career began at Bristol Myers Squibb, where she developed a strong foundation in the pharmaceutical sector. She then spent a decade at Pfizer, contributing to pivotal clinical research initiatives. Her 15-year tenure at PPD further solidified her expertise across various therapeutic areas, including oncology, haematology, cardiovascular, metabolic, gastrointestinal, liver and immunology. Most recently, Vignola spent three years at Thermo Fisher Scientific, where she played a key role in driving clinical trial strategies and ensuring operational excellence.
In her latest role, Vignola will oversee the cardiovascular and metabolic business unit, leading Worldwide’s therapeutically-focused team and partnering with sponsors to advance new medications through clinical development while driving business growth for Worldwide. Her appointment comes at a pivotal time for the cardiovascular and metabolic sectors, which are undergoing rapid advancements, particularly in the areas of diabetes and obesity, as well as across all cardiovascular-kidney-metabolic diseases, including metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease, and other acute and chronic liver diseases.
“Today’s cardiovascular and metabolic markets are marked by significant challenges and opportunities. Cardiovascular diseases remain the leading cause of mortality worldwide, while metabolic disorders, including diabetes and obesity, are increasing at an alarming rate,” said Vignola. “I’m happy to join this team and drive more advancements in these areas for patients around the world.”
Dave Bowser, chief operating officer at Worldwide Clinical Trials, said: “Alessandra’s deep understanding of the cardiovascular and metabolic markets, combined with her proven track record of leading successful clinical programmes, makes her an exceptional addition to our team.”